US · SBFM
Sunshine Biopharma, Inc.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Pointe-Claire, QC H9R 0A5
- Website
- sunshinebiopharma.com
Price · as of 2024-12-31
$1.06
Market cap 5.89M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $53.28 | +4,950.24% |
| Intrinsic Value(DCF) | $779,341.75 | +73,871,155.92% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | $0.00 | ||||
| 2019 | $0.00 | $78,010.57 | |||
| 2020 | $0.00 | $0.00 | |||
| 2021 | $5,840.00 | $222,055.23 | $971,703,198.95 | $0.00 | $0.00 |
| 2022 | $1,740.00 | $12,007.61 | $19,916,679,982.94 | $0.00 | $0.00 |
| 2023 | $116.00 | $3,322.38 | $244,067,121,952.28 | $0.00 | $0.00 |
| 2024 | $2.39 | $53.28 | $42,412,428.95 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Sunshine Biopharma, Inc.'s (SBFM) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $53.28
- Current price
- $1.06
- AI upside
- +4,950.24%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$779,341.75
+73,871,155.92% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| SBFM | Sunshine Biopharma, Inc. | $1.06 | 5.89M | +4,950% | +73,871,156% | — | — | -0.33 | 0.07 | 0.05 | 1.37 | — | 0.08 | 30.60% | -16.67% | -14.72% | -22.97% | -54.65% | -17.73% | 0.04 | -662.41 | 4.11 | 2.15 | 1.69 | -9792.00% | 4475.00% | 5530.00% | -885.54% | -1.98 | -146.04% | 0.00% | 0.00% | 187.20% | 1.21 | 0.48 | -0.20 | -1.74 |
| ACXP | Acurx Pharmaceuticals, In… | $1.50 | 2.38M | — | — | — | — | -0.55 | 12.65 | — | — | — | 12.65 | 0.00% | — | — | -534.03% | 478.14% | -243.85% | 0.00 | — | 1.19 | 1.16 | — | -2355.00% | — | 594.00% | -133.41% | -3.20 | 352.03% | 0.00% | 0.00% | 0.00% | -0.29 | -0.39 | — | -34.86 |
| BFRI | Biofrontera Inc. | $0.91 | 10.62M | +16,739% | -59% | — | — | -0.29 | 1.14 | 0.14 | -0.28 | — | 1.15 | 50.12% | -46.14% | -47.61% | -384.98% | -281.81% | -70.99% | 1.11 | -8.17 | 1.72 | 0.93 | 0.07 | -7527.00% | 949.00% | -5851.00% | -203.55% | -0.85 | -169.15% | 0.00% | 0.00% | 99.29% | -0.24 | -0.40 | 0.11 | -7.68 |
| CHEK | Check-Cap Ltd. | $1.68 | 9.83M | — | — | — | — | -0.19 | -3.24 | — | -0.49 | -0.43 | -3.24 | 0.00% | — | — | -226.19% | 1959.89% | -198.07% | -0.09 | -2883.22 | 0.15 | 0.15 | -0.01 | 4333.00% | — | -9995.00% | -0.17% | 0.00 | 0.60% | 0.00% | 0.00% | 0.00% | -0.18 | -570.68 | — | -861.86 |
| EVOK | Evoke Pharma, Inc. | $11.00 | 18.95M | +308% | +3,860,968% | — | — | -1.38 | 1.05 | 0.72 | 0.22 | — | 1.05 | 96.52% | -50.77% | -52.22% | -240.09% | 280.01% | -43.54% | 0.73 | -10.38 | 1.66 | 1.54 | 1.74 | -8995.00% | 9784.00% | 950.00% | -73.85% | -0.53 | 293.71% | 0.00% | 0.00% | 117.66% | 0.20 | 0.19 | -0.10 | -9.79 |
| HCWB | HCW Biologics Inc. | $0.54 | 1.16M | +6,101% | +980% | — | +51% | -18.86 | -83.66 | 220.66 | -20.79 | -188.64 | -83.66 | 37.38% | -1148.50% | -1169.70% | -897.37% | -320.11% | -102.21% | -2.02 | -25.45 | 0.19 | 0.18 | -0.33 | 1000.00% | -968.00% | -4954.00% | -2.56% | -0.48 | -157.33% | 0.00% | 0.00% | 0.00% | -19.52 | -39.71 | 224.17 | 0.44 |
| IINN | Inspira Technologies Oxy … | $0.58 | 13.97M | — | — | — | — | -1.42 | 3.64 | — | -1121.82 | — | 3.64 | 0.00% | — | — | -219.74% | 7.39% | -127.19% | 0.58 | — | 2.02 | 1.71 | 234.68 | -9994.00% | — | -426.00% | -60.68% | -2.78 | -6254.43% | 0.00% | 0.00% | 0.00% | 1104.79 | -1.31 | — | -8.52 |
| LUCY | Innovative Eyewear, Inc. | $1.12 | 5.12M | +2,253% | +40,227,901% | — | — | -0.81 | 0.69 | 3.84 | 0.16 | — | 0.73 | 13.15% | -484.20% | -474.60% | -106.00% | -557.55% | -96.74% | 0.00 | — | 12.52 | 10.38 | 0.35 | -5904.00% | 4199.00% | 1643.00% | -111.49% | -9.14 | -493.01% | 0.00% | 0.00% | 0.00% | 0.16 | 0.18 | -0.76 | 0.10 |
| PFSA | Profusa, Inc. Common Stoc… | $1.04 | 579.06K | — | — | — | — | — | — | — | — | — | — | 0.00% | — | — | 8.05% | 6.39% | -371.73% | -0.40 | -1.02 | 0.00 | 0.00 | -9.99 | -968.00% | — | -5309.00% | — | -0.04 | 2.93% | — | 0.00% | — | — | — | — | — |
| SNOA | Sonoma Pharmaceuticals, I… | $2.90 | 5.02M | +34,823% | -54% | — | — | -1.19 | 0.93 | 0.29 | 0.27 | — | 0.93 | 38.25% | -25.97% | -24.20% | -65.55% | -250.76% | -24.32% | 0.07 | — | 3.09 | 2.23 | 1.42 | -4756.00% | 1219.00% | -9304.00% | -4.08% | -0.02 | -11.36% | 0.00% | 0.00% | 61.89% | 0.26 | 5.65 | -0.07 | -19.06 |
About Sunshine Biopharma, Inc.
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.
- CEO
- Steve N. Slilaty
- Employees
- 52
- Beta
- 1.55
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($779,341.75 ÷ $1.06) − 1 = +73,871,155.92% (DCF, example).